Trial Profile
VENOUS THROMBOEMBOLISM IN RENALLY IMPAIRED PATIENTS AND DIRECT ORAL ANTICOAGULANTS: The VERDICT Study
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 20 Oct 2022
Price :
$35
*
At a glance
- Drugs Apixaban (Primary) ; Rivaroxaban (Primary)
- Indications Venous thromboembolism
- Focus Therapeutic Use
- Acronyms VeRDICT
- 17 Oct 2022 Status changed from active, no longer recruiting to discontinued.
- 02 Feb 2022 Planned primary completion date changed from 1 Dec 2021 to 1 Jun 2022.
- 02 Feb 2022 Status changed from recruiting to active, no longer recruiting.